Seeking Alpha·3d ago
Precigen, Inc. (PGEN) Q3 2026 Earnings Call TranscriptPrecigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript
Precigen's reliance on non-recurring milestone payments to drive revenue growth, as evidenced by the $23.3M reported in 2026Q1, obscures a fundamental inability to achieve sustainable operational profitability.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.08+33.3% vs $0.06 | $74M+3.6% vs $72M |
Q3 2026 Aug 4, 2026 | $0.05+514.3% vs -$0.01 | $55M+96.5% vs $28M |
Q2 2026 May 13, 2026 | -$0.02+33.3% vs -$0.03 | $23M+11.8% vs $21M |
Q2 2026 Mar 25, 2026 | -$0.07+33.6% vs -$0.10 | $5M-45.6% vs $8M |
Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript
Precigen NASDAQ: PGEN reported $72.9 million in third-quarter 2026 sales of PAPZIMEOS, its treatment for adults with recurrent respiratory papillomatosis, as the company posted a second consecutive profitable quarter and generated positive cash flow ahead of its prior expectations.
Precigen, Inc. (PGEN) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.11 per share a year ago.
PAPZIMEOS ® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 bringing launch-to-date net product revenue to $151 million, underscoring sustained commercial momentum and expanding US adoption Achieved positive cash flow in the third quarter of 2026, a full quarter ahead of guidance, driven by robust PAPZIMEOS uptake Net income for the third quarter of $35.8 million Cash, cash equivalents, and investments totaled $51.0 million as of September 30, 2026 Received FDA Platform Technology Designation for the AdenoVerse ® platform, creating opportunities to expedite development of current and future therapies New long-term follow-up data presented at AAO-HNSF 2026 demonstrated ongoing durable complete responses after PAPZIMEOS treatment for up to five years Conference call scheduled for 4:30 PM ET today GERMANTOWN, Md., Nov. 4, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced third quarter 2026 financial results and business updates.
Benchmark PGEN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Precigen, Inc. (PGEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.47 | $1.59B | 77.20 | 146.73% | 15.55% | 57.93% | — | |
| $1.84 | $214.47M | -1.83 | -51.24% | -2619.64% | -73.92% | — | |
| $9.54 | $845.34M | -4.09 | 627.84% | -72.38% | -804.38% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $0.91 | $1.77M | -0.09 | -13.43% | -490.33% | -1035.26% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — |
Precigen, Inc. (PGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Precigen, Inc. (PGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 24, 2026·SEC
May 13, 2026·SEC
Get notified when PGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Precigen, Inc. (PGEN) stock FAQ — growth, dividends, profitability & financials explained
Precigen, Inc. (PGEN) reported $156.9M in revenue over the trailing twelve months. Revenue was $9.7M in fiscal year 2025. That is 21% more than the $8.0M of fiscal year 2011.
Precigen, Inc. (PGEN) grew revenue by 2387.6% over the trailing twelve months, compared with the twelve months before.
Yes. Precigen, Inc. (PGEN) earned $24.4M in net income over the trailing twelve months (a 15.6% net margin).
Precigen, Inc. (PGEN) had a return on equity (ROE) of 57.9% over the trailing twelve months. That is well above the market's typical 10-15%.
Precigen, Inc. (PGEN) had negative free cash flow of $74.9M over the trailing twelve months.
